{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:21:14Z","timestamp":1792102874530,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Polymerase eta (or Pol \u03b7 or POLH) is a specialized DNA polymerase that is able to bypass certain blocking lesions, such as those generated by ultraviolet radiation (UVR) or cisplatin, and is deployed to replication foci for translesion synthesis as part of the DNA damage response (DDR). Inherited defects in the gene encoding POLH (a.k.a., XPV) are associated with the rare, sun-sensitive, cancer-prone disorder, xeroderma pigmentosum, owing to the enzyme\u2019s ability to accurately bypass UVR-induced thymine dimers. In standard-of-care cancer therapies involving platinum-based clinical agents, e.g., cisplatin or oxaliplatin, POLH can bypass platinum-DNA adducts, negating benefits of the treatment and enabling drug resistance. POLH inhibition can sensitize cells to platinum-based chemotherapies, and the polymerase has also been implicated in resistance to nucleoside analogs, such as gemcitabine. POLH overexpression has been linked to the development of chemoresistance in several cancers, including lung, ovarian, and bladder. Co-inhibition of POLH and the ATR serine\/threonine kinase, another DDR protein, causes synthetic lethality in a range of cancers, reinforcing that POLH is an emerging target for the development of novel oncology therapeutics. Using a fragment-based drug discovery approach in combination with an optimized crystallization screen, we have solved the first X-ray crystal structures of small novel drug-like compounds, i.e., fragments, bound to POLH, as starting points for the design of POLH inhibitors. The intrinsic molecular resolution afforded by the method can be quickly exploited in fragment growth and elaboration as well as analog scoping and scaffold hopping using medicinal and computational chemistry to advance hits to lead. An initial small round of medicinal chemistry has resulted in inhibitors with a range of functional activity in an <jats:italic>in vitro<\/jats:italic> biochemical assay, leading to the rapid identification of an inhibitor to advance to subsequent rounds of chemistry to generate a lead compound. Importantly, our chemical matter is different from the traditional nucleoside analog-based approaches for targeting DNA polymerases.<\/jats:p>","DOI":"10.3389\/fonc.2021.778925","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T09:49:01Z","timestamp":1637315341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)"],"prefix":"10.3389","volume":"11","author":[{"suffix":"3rd","given":"David M.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A. J.","family":"Duncton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Lee Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis M.","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pellicena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanu","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.09.004","article-title":"DNA Repair Inhibition: A Selective Tumour Targeting Strategy","volume":"11","author":"Madhusudan","year":"2005","journal-title":"Trends Mol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA Repair Pathways as Targets for Cancer Therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG Inhibitors in Cancer Treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30155","article-title":"DNA Polymerase Eta: A Potential Pharmacological Target for Cancer Therapy","volume":"236","author":"Saha","year":"2020","journal-title":"J\u00a0Cell Physiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/bi500019s","article-title":"An Overview of Y-Family DNA Polymerases and a Case Study of Human DNA Polymerase \u03b7","volume":"53","author":"Yang","year":"2014","journal-title":"Biochemistry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3928","article-title":"A PolH Transcript With a Short 3\u2019utr Enhances PolH Expression and Mediates Cisplatin Resistance","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.7b01176","article-title":"A Small-Molecule Inhibitor of Human DNA Polymerase \u03b7 Potentiates the Effects of Cisplatin in Tumor Cells","volume":"57","author":"Zafar","year":"2018","journal-title":"Biochemistry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421365112","article-title":"Enhanced Expression of DNA Polymerase Eta Contributes to Cisplatin Resistance of Ovarian Cancer Stem Cells","volume":"112","author":"Srivastava","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1148242","article-title":"Bypass of DNA Lesions Generated During Anticancer Treatment With Cisplatin by DNA Polymerase Eta","volume":"318","author":"Alt","year":"2007","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1158\/0008-5472.CAN-05-1095","article-title":"A Role for Polymerase Eta in the Cellular Tolerance to Cisplatin-Induced Damage","volume":"65","author":"Albertella","year":"2005","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1328","article-title":"The Role of DNA Polymerase Eta in Translesion Synthesis Past Platinum-DNA Adducts in Human Fibroblasts","volume":"64","author":"Bassett","year":"2004","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/bi000130k","article-title":"Efficient Translesion Replication Past Oxaliplatin and Cisplatin GpG Adducts by Human DNA Polymerase Eta","volume":"39","author":"Vaisman","year":"2000","journal-title":"Biochemistry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102848","article-title":"Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass","volume":"12","author":"Wilkinson","year":"2020","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062917-012405","article-title":"Translesion and Repair DNA Polymerases: Diverse Structure and Mechanism","volume":"87","author":"Yang","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01988-18","article-title":"Lsm12 Mediates Deubiquitination of DNA Polymerase \u03b7 To Help Saccharomyces Cerevisiae Resist Oxidative Stress","volume":"85","author":"Yao","year":"2019","journal-title":"Appl Environ Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812856115","article-title":"Bypassing a 8,5\u2019-Cyclo-2'-Deoxyadenosine Lesion by Human DNA Polymerase \u03b7 at Atomic Resolution","volume":"115","author":"Weng","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107779200","article-title":"Oxygen Free Radical Damage to DNA. Translesion Synthesis by Human DNA Polymerase Eta and Resistance to Exonuclease Action at Cyclopurine Deoxynucleoside Residues","volume":"276","author":"Kuraoka","year":"2001","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1479-5876-8-126","article-title":"DNA Polymerase \u03b7 Protein Expression Predicts Treatment Response and Survival of Metastatic Gastric Adenocarcinoma Patients Treated With Oxaliplatin-Based Chemotherapy","volume":"8","author":"Teng","year":"2010","journal-title":"J Trans Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e83978","DOI":"10.1371\/journal.pone.0083978","article-title":"Expression of DNA Translesion Synthesis Polymerase \u03b7 in Head and Neck Squamous Cell Cancer Predicts Resistance to Gemcitabine and Cisplatin-Based Chemotherapy","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3931","article-title":"DNA Polymerase Eta Prevents Tumor Cell-Cycle Arrest and Cell Death During Recovery From Replication Stress","volume":"78","author":"Barnes","year":"2018","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.187","article-title":"Co-Inhibition of Pol \u03b7 and ATR Sensitizes Cisplatin-Resistant Non-Small Cell Lung Cancer Cells to Cisplatin by Impeding DNA Damage Repair","volume":"39","author":"Li","year":"2018","journal-title":"Acta Pharmacologica Sin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040795","article-title":"Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress Towards a Clinically-Successful ATR Inhibitor for Cancer Therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"B26","article-title":"Somatic Mutations in the DNA Damage-Response Genes ATR and CHK1 in Sporadic Stomach Tumors With Microsatellite Instability","volume":"61","author":"Menoyo","year":"2001","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.007925","article-title":"Human DNA Polymerase \u03b7 Has Reverse Transcriptase Activity in Cellular Environments","volume":"294","author":"Su","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1560","article-title":"Structural Basis for Inhibition of the RNA-Dependent RNA Polymerase From SARS-CoV-2 by Remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326","article-title":"Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, A Key Drug Target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J Proteome Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of Sofosbuvir for the Treatment of Hepatitis C Virus Infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann NY Acad Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trecan.2020.09.007","article-title":"Targeting the DNA Repair Enzyme Polymerase \u03b8 in Cancer Therapy","volume":"7","author":"Schrempf","year":"2021","journal-title":"Trends Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/cb400305r","article-title":"N-Aroyl Indole Thiobarbituric Acids as Inhibitors of DNA Repair and Replication Stress Response Polymerases","volume":"8","author":"Coggins","year":"2013","journal-title":"ACS Chem Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2020.10.005","article-title":"Fragment- and Structure-Based Drug Discovery for Developing Therapeutic Agents Targeting the DNA Damage Response","volume":"163","author":"Wilson","year":"2020","journal-title":"Prog Biophysics Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1107\/S0909049502015170","article-title":"Blu-Ice and the Distributed Control System: Software for Data Acquisition and Instrument Control at Macromolecular Crystallography Beamlines","volume":"9","author":"McPhillips","year":"2002","journal-title":"J\u00a0Synchrotron Radiat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallographica Section D Biol Crystallogr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 Suite and Current Developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallographica Section D Biol Crystallogr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/bs.mie.2017.03.022","article-title":"Detection of Reaction Intermediates in Mg2+-Dependent DNA Synthesis and RNA Degradation by Time-Resolved X-Ray Crystallography","volume":"592","author":"Samara","year":"2017","journal-title":"Methods Enzymology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"126717","DOI":"10.1016\/j.bmcl.2019.126717","article-title":"Discovery of Novel Cyclophilin D Inhibitors Starting From Three Dimensional Fragments With Millimolar Potencies","volume":"29","author":"Gr\u00e4dler","year":"2019","journal-title":"Bioorganic Medicinal Chem Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00007","article-title":"Fragment-Based Design of Mycobacterium Tuberculosis InhA\u00a0Inhibitors","volume":"63","author":"Sabbah","year":"2020","journal-title":"J\u00a0Medicinal Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00224","article-title":"Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design","volume":"63","author":"Chac\u00f3n Simon","year":"2020","journal-title":"J Medicinal Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:19:34Z","timestamp":1638314374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":41,"alternative-id":["10.3389\/fonc.2021.778925"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.778925","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"article-number":"778925"}}